Trial · NCT02259517
An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
NCT02259517, Not applicable, Terminated, New York State Psychiatric Institute; results first posted 2023-02-02
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD. Trials, record NCT02259517. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02259517
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An fMRI Study of Stimulant vs. Non-Stimulant Treatment of ADHD
- NCT number
- NCT02259517
- Status
- Terminated
- Phases
- Not applicable
- Enrollment
- 38 participants, actual
- Lead sponsor
- New York State Psychiatric Institute
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Guanfacine, Lisdexamfetamine
- First posted
- 2014-10-08
- Last updated
- 2023-02-02
- Results first posted
- 2023-02-02
- Limitations and caveats
No statistical analysis information is being submitted for the affected outcome measure. No statistical analyses have been performed or would be considered scientifically appropriate because actual enrollment fell well below target enrollment. Enrollment terminated early as a result of the COVID-19 pandemic.
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Changes in Brain Segmentation Volume Produced by Stimulant or Non-stimulant Medications in Patients With ADHD | Baseline and 6 weeks | Brain segmentation volume measured in mm\^3. We are reporting the mean difference in brain segmentation volume from baseline (pre-test) to 6 weeks (post-test). No statistical analysis information is being submitted for the affected outcome measure. No statistical analyses have been performed or would be considered scientifically appropriate because actual enrollment fell well below target enrollment. Enrollment terminated early as a result of the COVID-19 pandemic. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Changes in Brain Segmentation Volume Produced by Stimulant or Non-stimulant Medications in Patients With ADHD | Baseline and 6 weeks | 4 subjects from the ADHD-Guanfacine group and 3 subjects from the ADHD-Lisdexamfetamine group had usable anatomical MRI data at baseline and follow-up. HCs did not complete follow-up.~No statistical analysis information is being submitted for the affected outcome measure. No statistical analyses have been performed or would be considered scientifically appropriate because actual enrollment fell well below target enrollment. Enrollment terminated early as a result of the COVID-19 pandemic. | mm^3 | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Changes in Brain Segmentation Volume Produced by Stimulant or Non-stimulant Medications in Patients With ADHD | ADHD - Guanfacine | -6137 | Standard Deviation 14393 | mm^3 | |
| Changes in Brain Segmentation Volume Produced by Stimulant or Non-stimulant Medications in Patients With ADHD | ADHD - Lisdexamfetamine | 11833 | Standard Deviation 39942 | mm^3 |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ADHD - Guanfacine | 5 | |
| Overall Study | STARTED | ADHD - Lisdexamfetamine | 4 | |
| Overall Study | STARTED | Healthy Controls | 24 | |
| Overall Study | COMPLETED | ADHD - Guanfacine | 5 | |
| Overall Study | COMPLETED | ADHD - Lisdexamfetamine | 4 | |
| Overall Study | COMPLETED | Healthy Controls | 15 | |
| Overall Study | NOT COMPLETED | ADHD - Guanfacine | 0 | |
| Overall Study | NOT COMPLETED | ADHD - Lisdexamfetamine | 0 | |
| Overall Study | NOT COMPLETED | Healthy Controls | 9 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Guanfacine | 0 | 5 |
| Total, all-cause mortality | Lisdexamfetamine | 0 | 4 |
| Total, other adverse events | Guanfacine | 0 | 5 |
| Total, other adverse events | Lisdexamfetamine | 0 | 4 |
| Total, serious adverse events | Guanfacine | 0 | 5 |
| Total, serious adverse events | Lisdexamfetamine | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Guanfacine vs Lisdexamfetamine: deaths from any cause | Trial comparisons |
| Guanfacine vs Lisdexamfetamine: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02259517
GET https://conductscience.org/api/trials/v1/NCT02259517/registered